These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 32311641

  • 21. An experimental model for Huntington's chorea?
    Zeef DH, Jahanshahi A, Vlamings R, Casaca-Carreira J, Santegoeds RG, Janssen ML, Oosterloo M, Temel Y.
    Behav Brain Res; 2014 Apr 01; 262():31-4. PubMed ID: 24412685
    [Abstract] [Full Text] [Related]

  • 22. Tardive dyskinesia caused by tetrabenazine.
    LeWitt PA.
    Clin Neuropharmacol; 2013 Apr 01; 36(3):92-3. PubMed ID: 23673911
    [Abstract] [Full Text] [Related]

  • 23. Long-term effects of tetrabenazine in hyperkinetic movement disorders.
    Jankovic J, Beach J.
    Neurology; 1997 Feb 01; 48(2):358-62. PubMed ID: 9040721
    [Abstract] [Full Text] [Related]

  • 24. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H, Jankovic J.
    Expert Rev Neurother; 2018 Aug 01; 18(8):625-631. PubMed ID: 29996061
    [Abstract] [Full Text] [Related]

  • 25. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO, Philbin M, Carroll B.
    Expert Opin Pharmacother; 2019 Dec 01; 20(18):2209-2221. PubMed ID: 31613641
    [Abstract] [Full Text] [Related]

  • 26. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C, Hunter C, Jankovic J.
    Mov Disord; 2007 Jan 15; 22(2):193-7. PubMed ID: 17133512
    [Abstract] [Full Text] [Related]

  • 27. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM, Nicewonder JA.
    J Pharm Pract; 2019 Aug 15; 32(4):450-457. PubMed ID: 29455579
    [Abstract] [Full Text] [Related]

  • 28. The effect of tetrabenazine in some hyperkinetic syndromes.
    Pakkenberg H.
    Acta Neurol Scand; 1968 Aug 15; 44(3):391-3. PubMed ID: 4235247
    [No Abstract] [Full Text] [Related]

  • 29. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine.
    Setter SM, Neumiller JJ, Dobbins EK, Wood L, Clark J, DuVall CA, Santiago A.
    Consult Pharm; 2009 Jul 15; 24(7):524-37. PubMed ID: 19689181
    [Abstract] [Full Text] [Related]

  • 30. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N, Jimenez-Shahed J.
    Neurodegener Dis Manag; 2019 Apr 15; 9(2):59-71. PubMed ID: 30702019
    [Abstract] [Full Text] [Related]

  • 31. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN, Aggarwal S, Yonan C.
    J Comp Eff Res; 2018 Feb 15; 7(2):135-148. PubMed ID: 28965423
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Tetrabenazine for involuntary movement disorders.
    Kingston D.
    Med J Aust; 1979 Jun 30; 1(13):628-30. PubMed ID: 158700
    [Abstract] [Full Text] [Related]

  • 35. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):61-68. PubMed ID: 28839341
    [Abstract] [Full Text] [Related]

  • 36. Effect of tetrabenazine on extrapyramidal movement disorders.
    Dalby MA.
    Br Med J; 1969 May 17; 2(5654):422-3. PubMed ID: 4238453
    [Abstract] [Full Text] [Related]

  • 37. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.
    Jankovic J.
    Ann Neurol; 1982 Jan 17; 11(1):41-7. PubMed ID: 6460467
    [Abstract] [Full Text] [Related]

  • 38. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM.
    CNS Spectr; 2018 Aug 17; 23(4):239-247. PubMed ID: 30160230
    [Abstract] [Full Text] [Related]

  • 39. Analysis of CYP2D6 genotype and response to tetrabenazine.
    Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J.
    Mov Disord; 2013 Feb 17; 28(2):210-5. PubMed ID: 23280482
    [Abstract] [Full Text] [Related]

  • 40. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
    Dean M, Sung VW.
    Drug Des Devel Ther; 2018 Feb 17; 12():313-319. PubMed ID: 29497277
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.